Investigating how a specific protein modification affects T cell function in cancer treatment

Phosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T Cells

NIH-funded research Johns Hopkins University · NIH-11059253

This study is looking at how a protein called TSC2 affects T cells, which are important for fighting cancer, and how changing a specific part of this protein might help make T cells work better in cancer treatments.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11059253 on NIH RePORTER

What this research studies

This research focuses on understanding the role of a protein called TSC2 in regulating T cell activation and function, particularly in the context of cancer immunotherapy. The study examines how a specific modification of TSC2, known as phosphorylation at site S1365, influences the activity of a signaling pathway called mTORC1 in T cells. By manipulating this phosphorylation, researchers aim to enhance T cell responses against tumors while also considering the implications for memory T cell generation. This could lead to improved strategies for adoptive cell therapies in cancer treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers who may benefit from enhanced T cell therapies.

Not a fit: Patients with conditions unrelated to T cell function or those not undergoing cancer treatment may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer immunotherapies by optimizing T cell responses.

How similar studies have performed: Other research has shown promising results in manipulating T cell signaling pathways for improved cancer treatment outcomes.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapyBourneville DiseaseBourneville syndrome
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.